Protagonist Therapeutics (PTGX) Income from Continuing Operations (2017 - 2025)
Historic Income from Continuing Operations for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to -$39.3 million.
- Protagonist Therapeutics' Income from Continuing Operations fell 1845.53% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.9 million, marking a year-over-year decrease of 7314.91%. This contributed to the annual value of $275.2 million for FY2024, which is 44853.78% up from last year.
- As of Q3 2025, Protagonist Therapeutics' Income from Continuing Operations stood at -$39.3 million, which was down 1845.53% from -$34.8 million recorded in Q2 2025.
- Over the past 5 years, Protagonist Therapeutics' Income from Continuing Operations peaked at $207.3 million during Q1 2024, and registered a low of -$41.0 million during Q2 2022.
- In the last 5 years, Protagonist Therapeutics' Income from Continuing Operations had a median value of -$33.2 million in 2024 and averaged -$7.5 million.
- In the last 5 years, Protagonist Therapeutics' Income from Continuing Operations tumbled by 33545.02% in 2021 and then skyrocketed by 71479.61% in 2024.
- Protagonist Therapeutics' Income from Continuing Operations (Quarter) stood at -$37.2 million in 2021, then increased by 7.77% to -$34.3 million in 2022, then skyrocketed by 179.78% to $27.3 million in 2023, then surged by 381.7% to $131.7 million in 2024, then crashed by 129.88% to -$39.3 million in 2025.
- Its Income from Continuing Operations was -$39.3 million in Q3 2025, compared to -$34.8 million in Q2 2025 and -$11.7 million in Q1 2025.